MedElevator Войти в исследования
← Поиск публикаций

DOI 10.61882/ijkd.20.4.9579

Медицинская библиотека · Iranian journal of kidney diseases · 2026

Effect of Melatonin Supplementation on Glycemic and Lipid Profiles in Kidney Transplant Recipients: A Clinical Trial.

Pourrezagholi Fatemeh, Amini Hossein, Omid Moradi, Mahdavi Behnam, Nadiri Niri Aylar, Taherpour Niloufar, Ameri Sahand, Sistanizad Mohammad, Kafi Parinaz

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Melatonin plays a crucial role in regulating sleep and has potent antioxidant properties. However, the relationship between melatonin supplementation and metabolic factors related to diabetes and lipid profiles-which are associated with increased mortality in kidney transplant recipients has not yet been fully clarified.

METHODS

This randomized, double-blind, placebo-controlled trial was conducted at Labbafinejad Hospital, Tehran, Iran. Adult kidney transplant recipients (≥6 months post-transplant) received either 6 mg/day melatonin or placebo for three months. A modified intention-to-treat analysis included 42 patients per group. The primary outcomes were changes in fasting blood sugar (FBS) and HbA1c levels, while secondary outcomes included blood pressure and lipid profile parameters. Between-group effects were estimated using linear regression adjusted for baseline values and confounders.

RESULTS

In the melatonin group, FBS decreased by a median of 6.5 mg/dL (P < .001) and HbA1c by 0.25 units (P < .001), whereas both parameters increased in the placebo group. The adjusted between-group effect favored melatonin for HbA1c (β = -0.30%; 95% CI: -0.59 to -0.01; P < .001) but not for FBS (β = -2.61 mg/dL; 95% CI: -17.93 to 12.71; P = .283). Triglyceride levels decreased by 16 mg/dL in the melatonin group compared with an increase of 13.5 mg/dL in the placebo group (adjusted β = -23.77 mg/dL; 95% CI: -45.50 to -2.04; P = .032). No significant differences were observed in blood pressure and renal function.

CONCLUSION

Melatonin supplementation for three months modestly improved glycemic control and lowered serum triglyceride levels in kidney transplant recipients, with no effects on blood pressure or kidney function. These results support melatonin's potential as an adjunct therapy for metabolic dysregulation in this population, warranting further investigation into its long-term benefits.

Для цитирования: Pourrezagholi Fatemeh, Amini Hossein, Omid Moradi, Mahdavi Behnam, Nadiri Niri Aylar, Taherpour Niloufar, Ameri Sahand, Sistanizad Mohammad, Kafi Parinaz. Effect of Melatonin Supplementation on Glycemic and Lipid Profiles in Kidney Transplant Recipients: A Clinical Trial.. Iranian journal of kidney diseases. 2026. DOI: 10.61882/ijkd.20.4.9579.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.